Search
Bedaquiline
go.drugbank.com/drugs/DB08903ApprovedInvestigational[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. … [A261866] Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP.
Categories: Antiinfectives for Systemic Use, Drugs for Treatment of TuberculosisMethadone
go.drugbank.com/drugs/DB00333ApprovedInvestigationalThe intention of substitution of illicit opioids with the long-acting opioids used in OAT is to prevent withdrawal symptoms for 24-36 hours following dosing to ultimately reduce cravings and drug-seeking … [F4685,F4688,F4691,A185885,A185900,A185903] Due to its unique mechanism of action, methadone is particularly useful for the management of hard to treat pain syndromes such as neuropathic pain and cancer
Categories: Drugs Used in Opioid Dependence, Drugs Used in Addictive DisordersArtenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalIt was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim. … Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label].
Magnesium gluconate
go.drugbank.com/drugs/DB13749ApprovedWithdrawnIn addition, it has been studied for its effects on premature uterine contractions [A32808]. … Although magnesium is available in the form of sulphates, lactate, hydroxide, oxide and chloride, only magnesium gluconate is recommended for magnesium supplementation as it appears to be better absorbed
Mixtures: K-medLevacetylmethadol
go.drugbank.com/drugs/DB01227ApprovedWithdrawnLevacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well.[L44052,T862] … Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.
Categories: Drugs Used in Opioid Dependence, Drugs Used in Addictive DisordersLisdexamfetamine
go.drugbank.com/drugs/DB01255ApprovedInvestigational[A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009. … [L48285] Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder [A2230] by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal
Categories: Psychostimulants, Agents Used for ADHD and Nootropics, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSerine/threonine-protein kinase Nek9
go.drugbank.com/bio_entities/BE0009500TargetHumansImportant for G1/S transition and S phase progression (PubMed:12840024, PubMed:14660563, PubMed:19941817). … Pleiotropic regulator of mitotic progression, participating in the control of spindle dynamics and chromosome separation (PubMed:12101123, PubMed:12840024, PubMed:14660563, PubMed:19941817).
Synonyms: Never in mitosis A-related kinase 9Casimersen
go.drugbank.com/drugs/DB14984ApprovedInvestigational[A218186] Casimersen is the most recent in a line of approved PMOs for treating DMD, including [eteplirsen] and [viltolarsen]. … [A218171, A218176, A229988] The application of antisense oligonucleotides in DMD patients with specific mutations allows for exon skipping to produce truncated BMD-like dystrophin proteins, which restore
Categories: Compounds used in a research, industrial, or household settingLasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigational[A187316,A187322] Lasmiditan, in contrast, is a highly selective agonist of 5-HT<sub>1F</sub> receptors, carrying virtually no affinity for other receptors which appear to be largely responsible for … Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePalbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigational[L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male … Palbociclib is a piperazine pyridopyrimidine[A176792] that acts in the cell cycle machinery.